Pharma companies set for strong performance in March 2025 quarter amid earning (...)
Sun Pharma is expected to post a 9% year-on-year revenue growth, supported by its US specialty portfolio and steady growth in chronic therapies in India.
Site référencé: The Economic Times
The Economic Times
RBI panel suggests longer call money hours, extended repo timings
2/05/2025
Market Wrap : D-St ends third week in green on foreign inflows, US trade deal optimism ; Sensex adds 260 pts, Nifty above (...)
2/05/2025
Mumbai has property selling for Rs 2 lakh a sq feet but Bangalore, Delhi NCR slowing down : Gulam Zia
2/05/2025
Hybrid funds the way forward amid soft macros and valuation reset : Vetri Subramaniam
2/05/2025
SC scraps JSW Steel’s ‘illegal’ Bhushan Power and Steel deal, orders liquidation
2/05/2025
Eternal shares jump 2% after Q4 results. Should you buy, sell or hold ?
2/05/2025
